AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $196,360 | +3.4% | 16,148 | +6.8% | 0.01% | +11.1% |
| Q2 2023 | $189,920 | +16.0% | 15,121 | +2.4% | 0.01% | +12.5% |
| Q1 2023 | $163,766 | -20.9% | 14,767 | -12.9% | 0.01% | -11.1% |
| Q4 2022 | $207,106 | +22.7% | 16,962 | +4.9% | 0.01% | +12.5% |
| Q3 2022 | $168,763 | -2.8% | 16,165 | 0.0% | 0.01% | 0.0% |
| Q2 2022 | $173,612 | +13.4% | 16,165 | 0.0% | 0.01% | +60.0% |
| Q1 2022 | $153,083 | -80.5% | 16,165 | -76.3% | 0.01% | -54.5% |
| Q4 2021 | $786,740 | +18.1% | 68,116 | -2.4% | 0.01% | +10.0% |
| Q3 2021 | $666,179 | -8.3% | 69,757 | -7.4% | 0.01% | 0.0% |
| Q2 2021 | $726,258 | +4.3% | 75,338 | +6.9% | 0.01% | 0.0% |
| Q1 2021 | $696,273 | -58.8% | 70,473 | -3.6% | 0.01% | -60.0% |
| Q4 2020 | $1,688,179 | +62.9% | 73,113 | -0.4% | 0.02% | +38.9% |
| Q3 2020 | $1,036,380 | -12.9% | 73,398 | -6.9% | 0.02% | -14.3% |
| Q2 2020 | $1,189,254 | +67.1% | 78,863 | +2.4% | 0.02% | +40.0% |
| Q1 2020 | $711,776 | -8.2% | 77,032 | -3.3% | 0.02% | +15.4% |
| Q4 2019 | $775,499 | +18.2% | 79,620 | -2.7% | 0.01% | +18.2% |
| Q3 2019 | $656,132 | -17.8% | 81,812 | +27.9% | 0.01% | -15.4% |
| Q2 2019 | $798,432 | -4.7% | 63,977 | +3.8% | 0.01% | -13.3% |
| Q1 2019 | $838,209 | +42.0% | 61,633 | 0.0% | 0.02% | +25.0% |
| Q4 2018 | $590,444 | -20.8% | 61,633 | 0.0% | 0.01% | -7.7% |
| Q3 2018 | $745,143 | -99.9% | 61,633 | 0.0% | 0.01% | -18.8% |
| Q2 2018 | $962,707,000 | +5.7% | 61,633 | +1.7% | 0.02% | +23.1% |
| Q1 2018 | $911,183,000 | +121229.3% | 60,584 | +16.1% | 0.01% | +30.0% |
| Q4 2017 | $751,000 | -55.1% | 52,172 | -53.0% | 0.01% | 0.0% |
| Q3 2017 | $1,674,000 | +62.2% | 111,027 | +8.4% | 0.01% | +42.9% |
| Q2 2017 | $1,032,000 | +41.2% | 102,462 | 0.0% | 0.01% | +40.0% |
| Q1 2017 | $731,000 | +51.0% | 102,462 | +5.2% | 0.01% | +66.7% |
| Q4 2016 | $484,000 | -36.7% | 97,421 | -5.8% | 0.00% | -50.0% |
| Q3 2016 | $765,000 | +50.6% | 103,437 | +11.2% | 0.01% | +50.0% |
| Q2 2016 | $508,000 | -25.8% | 92,989 | +14.6% | 0.00% | -20.0% |
| Q1 2016 | $685,000 | -13.0% | 81,108 | 0.0% | 0.01% | -16.7% |
| Q4 2015 | $787,000 | -30.7% | 81,108 | 0.0% | 0.01% | -25.0% |
| Q3 2015 | $1,135,000 | +15.7% | 81,108 | +17.0% | 0.01% | +14.3% |
| Q2 2015 | $981,000 | – | 69,319 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |